Allegheny Health Network | Strategic Alliance Partners

Christie J. Hilton, DO, details the evolving role of trastuzumab deruxtecan in HER2-positive breast cancer and the potential to de-escalate therapy in early-stage disease.

Colin E. Champ, MD, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-stage breast cancer.

Christie J. Hilton, DO, discusses the impact of trastuzumab deruxtecan on the treatment of patients with HER2-positive metastatic breast cancer and ongoing research with the agent in this patient population.

In this sixth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight the success seen with checkpoint inhibitors in gynecologic cancers, biomarkers of interest, and recent approvals in the space.

In this fifth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss PD-1 blockade, potential biomarkers of response to treatment with immunotherapy, and the potential for these agents in the neoadjuvant setting.

In this fourth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight long-term survival data reported with immunotherapy approaches in patients with gynecologic cancers.

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

In this third episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, review the 5 C's to consider when conducting research in gynecologic cancers and beyond.

In this second episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss the safety and efficacy of immunotherapy vs standard chemotherapy in patients with gynecologic cancers.

In this first episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, explain how immunotherapy has changed practice for the treatment of patients with gynecologic cancers.

In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.

In this fourth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss key developments made with PARP inhibitors in the ovarian cancer treatment paradigm.

In this third episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, explain the differences between germline and somatic testing in patients with ovarian cancer.

In this second episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how to counsel patients with ovarian cancer whose tumors harbor BRCA mutations.

In this first episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how BRCA mutational status affects treatment decisions for patients with ovarian cancer.

Colin Champ, MD, to lead AHN exercise oncology program at AGH Suburban Campus in Bellevue.

Allegheny Health Network’s Allegheny General and Forbes hospitals have earned distinguished three-star ratings from The Society of Thoracic Surgeons General Thoracic Surgery Database for their lung cancer resection surgery program.

Allegheny Health Network Cancer Institute and Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling to enhance patient care. 

Howard D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.

Howard D. Edington, MD, discusses the utilization of tumor-infiltrating lymphocyte therapy in melanoma.

Rebecca D. Edmonds, MD, a surgical oncologist specializing in the treatment of diseases of the liver, pancreas, gallbladder, spleen, colon, thyroid and breast, has joined the Allegheny Health Network Cancer Institute.

Eirwen M. Miller, MD, discusses the current treatment landscape of ovarian cancer.

Howard D. Edington, MD, discusses the importance of prevention strategies in melanoma.

Howard D. Edington, MD, discusses the evolving treatment paradigm of melanoma.

Benny Weksler, MD, MBA, FACS, FACCP, discusses efforts being made at Allegheny Health Network Cancer Institute to address disparities in the delivery of care and its impact on the screening and treatment of lung cancer.

John Lister, MD, discusses selecting patients with lymphoma for CAR T-cell therapy.

Clinicians at the AHN Cancer Institute are taking a giant leap forward in CAR T-cell therapy.

Trevor Batey was enjoying the first years of marriage and his work as a truck driver when cancer put the brakes on his life. He was in his early 20s when he saw blood in his stool, had a colonoscopy, and was diagnosed with colorectal cancer.

Allegheny Health Network announced its new Center for Genetics and Precision Medicine, which will provide highly personalized and precise medicine by uncovering patients’ DNA changes within cancer cells to determine effective treatments.